John H Kehne
Overview
Explore the profile of John H Kehne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klein B, Jacobson C, Metcalf C, Smith M, Wilcox K, Hampson A, et al.
Neurochem Res
. 2017 May;
42(7):1939-1948.
PMID: 28478594
Cannabidiol (CBD) is a cannabinoid component of marijuana that has no significant activity at cannabinoid receptors or psychoactive effects. There is considerable interest in CBD as a therapy for epilepsy....
2.
Kehne J, Klein B, Raeissi S, Sharma S
Neurochem Res
. 2017 May;
42(7):1894-1903.
PMID: 28462454
For over 40 years, the National Institute of Neurological Disorders and Stroke/National Institutes of Health-funded Anticonvulsant Screening Program has provided a preclinical screening service for participants world-wide that helped identify/characterize...
3.
Ashby Jr C, Kehne J, Bartoszyk G, Renda M, Athanasiou M, Pierz K, et al.
Eur J Pharmacol
. 2013 Jul;
714(1-3):359-65.
PMID: 23872377
This study examined the effect of vilazodone, a combined serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist, paroxetine and fluoxetine on the sensitivity of 5-HT(1A) autoreceptors of serotonergic dorsal...
4.
Avram M, Spyker D, Kehne J, Cassella J
J Clin Pharmacol
. 2013 Feb;
53(2):140-50.
PMID: 23436259
Pharmacokinetics, pharmacodynamics, safety, and tolerability of inhaled zaleplon were assessed in healthy volunteers. Forty participants received 0.5, 1, 2, or 4 mg zaleplon or placebo as a thermally generated aerosol...
5.
Cain C, Maynard G, Kehne J
Expert Opin Investig Drugs
. 2012 Jul;
21(9):1323-50.
PMID: 22834476
Introduction: Post-traumatic stress disorder (PTSD) is a chronic debilitating psychiatric disorder resulting from exposure to a severe traumatic stressor and an area of great unmet medical need. Advances in pharmacological...
6.
Kwentus J, Riesenberg R, Marandi M, Manning R, Allen M, Fishman R, et al.
Bipolar Disord
. 2012 Feb;
14(1):31-40.
PMID: 22329470
Objective: The present study evaluated inhaled loxapine for the acute treatment of agitation in patients with bipolar I disorder. Methods: A Phase 3, randomized, double blind, placebo-controlled, parallel group inpatient...
7.
Hodgetts K, Ge P, Yoon T, De Lombaert S, Brodbeck R, Gulianello M, et al.
J Med Chem
. 2011 May;
54(12):4187-206.
PMID: 21618986
The design, synthesis, and structure-activity relationships of a novel series of pyrazines, acting as corticotropin releasing factor-1 (CRF-1) receptor antagonists, are described. Synthetic methodologies were developed to prepare a number...
8.
Lesem M, Tran-Johnson T, Riesenberg R, Feifel D, Allen M, Fishman R, et al.
Br J Psychiatry
. 2011 Jan;
198(1):51-8.
PMID: 21200077
Background: There is a need for a rapid-acting, non-injection, acute treatment for agitation. Aims: To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia. Method: This phase III, randomised,...
9.
Rowlett J, Kehne J, Sprenger K, Maynard G
Psychopharmacology (Berl)
. 2010 Nov;
214(4):855-62.
PMID: 21103864
Rationale: Zolpidem is a hypnotic drug that binds to γ-aminobutyric acid type A receptors but lacks consistently demonstrable anxiolytic efficacy. Methods: Rhesus monkeys (N = 4) were trained under a...
10.
Kehne J, Cain C
Pharmacol Ther
. 2010 Sep;
128(3):460-87.
PMID: 20826181
Adaptive responding to threatening stressors is of fundamental importance for survival. Dysfunctional hyperactivation of corticotropin releasing factor type-1 (CRF(1)) receptors in stress response system pathways is linked to stress-related psychopathology...